Latest 8-K filings

Neuronetics, Inc. announced its second quarter 2026 financial and operating results, highlighting a 9.1% increase in total revenue and a significant reduction in net loss.

Coya Therapeutics reported Q2 2026 results, noting progress in its ALSTARS Phase 2 ALS trial, FDA Fast Track designation for COYA 302, and plans for a new FTD study, while managing a net loss of $6.6 million.

Imunon, Inc. announced its second quarter 2026 financial results, highlighting strong enrollment in its Phase 3 OVATION 3 study for IMNN-001 and positive preliminary data from a minimal residual disease study.

Smithfield Foods announced record first half fiscal 2026 operating profit, driven by its vertically integrated model, despite a slight dip in net sales.

Big Sky Industrial Inc. announced strong Q2 2026 results, highlighting construction progress at its Carbon Hub, a five-year take-or-pay helium offtake agreement, and a corporate rebrand to BSIN.

1606 Corp. has entered into a strategic agreement with MDM Group LLC to market its 132-acre East Texas power campus to AI infrastructure operators and strategic buyers.

Hanmi Financial Corporation presented its Q2 2026 operating and financial performance, highlighting steady loan and deposit growth, robust capital ratios, and a diversified loan portfolio.

Terrestrial Energy Inc. reported significant progress in its IMSR reactor development, including NRC approval of key licensing documents and updated economic projections showing increased lifetime revenue per plant.

Joby Aviation announced its definitive agreement to acquire Resonant Sciences for approximately $500 million, aiming to scale its defense business and create a diversified growth platform.

Stardust Power Inc. announced the appointment of V. Ray Rivers, a seasoned capital markets and financial services executive, to its Board of Directors, effective August 10, 2026.

Prelude Therapeutics announced its second quarter 2026 financial results, highlighting progress in its oncology pipeline and a cash runway extending into Q2 2028.

Peabody Energy provided an update on its Centurion Mine, detailing progress in overcoming operational challenges and emphasizing its strategic importance in the metallurgical coal market.

Unusual Machines announces an investor presentation detailing accelerated growth strategies, a pending acquisition, and significant market opportunities driven by US drone manufacturing initiatives.

ClearSign Technologies Corporation announced the appointment of Larry M. Saddler, a former Global Technology Sponsor for Heat Transfer at ExxonMobil, to its Board of Directors, effective August 6, 2026.

Intensity Therapeutics announced the resumption of enrollment in its Phase 3 soft tissue sarcoma study and restarted patient treatment in its Phase 2 triple-negative breast cancer trial, alongside its second quarter 2026 financial results.

Bicara Therapeutics reports Q2 2026 progress, including strong enrollment in its pivotal FORTIFI-HN01 study and a planned CEO transition to Ryan Cohlhepp in January 2027.

Zura Bio announced the completion of enrollment for its TibuSHIELD and TibuSURE Phase 2 studies, with topline data expected in Q4 2026 and H1 2027, respectively, and plans to initiate a new Phase 2 study for tibulizumab in polymyalgia rheumatica by year-end 2026.

Sagimet Biosciences announced its second quarter 2026 financial results, highlighting a robust cash position and progress in its denifanstat and TVB-3567 clinical programs for acne treatment.

Littelfuse, Inc. announced the appointment of Todd Kelsey, CEO of Plexus Corp., to its Board of Directors and Compensation Committee, effective August 6, 2026.

Autolus Therapeutics plc announced robust second-quarter 2026 financial results, driven by significant AUCATZYL sales growth, leading to an increase in full-year revenue guidance and a strengthened financial position.

Neurogene Inc. announced positive second quarter 2026 financial results, highlighting significant advancements in its NGN-401 program for Rett syndrome, including compelling clinical data and an extended cash runway.

Ambiq Micro announced record quarterly net sales up 90% year-over-year for Q2 2026, driven by strong demand for its ultra-low-power semiconductor solutions for edge AI.

Incannex Healthcare Inc. announced the receipt of a final A$5.1 million R&D tax incentive refund, bringing the total non-dilutive capital received in 2026 to over A$11.2 million, significantly bolstering its financial flexibility.

Tango Therapeutics announced strong Phase 1/2 data for vopimetostat in pancreatic cancer, positioning it for Phase 3 development, and reported a cash position of $1.0 billion as of June 30, 2026.

Superior Group of Companies, Inc. has amended and restated its credit facilities, increasing capacity to $200 million with a maturity extension to August 2031.

CalciMedica reported Q2 2026 results, announcing a $49 million private placement to advance its pulmonary hypertension program and providing updates on its Auxora and CM5480 candidates.

C4 Therapeutics announced second quarter 2026 financial results, highlighting progress in its cemsidomide clinical trials and a strong cash runway extending to the end of 2028.

Vireo Growth Inc. announced robust second-quarter 2026 financial results, showcasing substantial year-over-year revenue growth fueled by strategic acquisitions and detailing plans for further expansion.

Hemab Therapeutics announced strong Q2 2026 results with significant pipeline progress, including new data for HMB-002 and HMB-003, and advancement of sutacimig towards Phase 3 trials, bolstered by a substantial cash position post-IPO.

CVRx, Inc. announced the departure of its Chief Revenue Officer, Robert John, and the appointment of Paul Verrastro as Interim Head of Sales.